ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Albumin solution: Drug information

Albumin solution: Drug information
(For additional information see "Albumin solution: Patient drug information" and see "Albumin solution: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Albuked 25;
  • Albuked 5;
  • Albumin-ZLB;
  • Albuminex;
  • AlbuRx;
  • Albutein;
  • Flexbumin;
  • Human Albumin Grifols [DSC];
  • Kedbumin;
  • Plasbumin-25;
  • Plasbumin-5
Brand Names: Canada
  • Alburex-25;
  • Alburex-5;
  • Octalbin;
  • Plasbumin-5
Pharmacologic Category
  • Blood Product Derivative;
  • Plasma Volume Expander, Colloid
Dosing: Adult

Dosage guidance:

Clinical considerations: Use 5% solution in hypovolemic patients or intravascularly depleted patients. Use 25% solution in patients in whom fluid and sodium intake is restricted or to mobilize fluids.

Usual dose: IV: 25 g; initial dose may be repeated in 15 to 30 minutes if response is inadequate.

Adult respiratory distress syndrome

Adult respiratory distress syndrome:

Note: Although listed in manufacturer's labeling, impact on major clinical outcome data (eg, mortality) is limited and the potential benefit remains to be seen (Ref).

25% albumin: IV: 25 g over 30 minutes (in combination with furosemide); may repeat at 8 hours (if necessary) for 3 days; titrate to fluid loss and normalization of serum total protein. Patients enrolled into the clinical trial had hypoproteinemia (total protein <6 g/dL) (Ref).

Cirrhotic ascites, therapeutic large volume paracentesis

Cirrhotic ascites, therapeutic large volume paracentesis (adjunctive agent):

25% albumin: IV: 6 to 8 g for every liter removed (Ref) or 50 g total for paracentesis >5 L (Ref). Note: Administer at the time of or soon after the procedure to avoid postparacentesis complications (eg, hypovolemia, hyponatremia, kidney impairment) (Ref).

Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment

Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment (adjunctive agent) (off-label use):

Note: Used before or in combination with norepinephrine, terlipressin, or midodrine plus octreotide (Ref).

25% albumin: IV: Initial: 1 g/kg daily for 2 days (maximum: 100 g/day), followed by 20 to 50 g daily until clinical outcome is achieved (Ref).

Hypovolemia

Hypovolemia: Note: For replacement of volume deficit, 5% albumin is generally preferred.

IV: Initial: 12.5 to 25 g (250 to 500 mL); repeat after 15 to 30 minutes as needed (if hemodynamic stability is not achieved). Note: In patients with sepsis or septic shock, may consider after inadequate response to large volumes of crystalloid therapy. The volume administered and the rate of infusion should be adapted to individual response (Ref).

Ovarian hyperstimulation syndrome

Ovarian hyperstimulation syndrome (treatment): 25% albumin: IV: 50 to 100 g over 4 hours; repeat at 4 to 12 hours intervals as needed.

Plasma exchange, therapeutic

Plasma exchange, therapeutic: 5% albumin: IV: Titrate dose to plasma volume removed during procedure.

Spontaneous bacterial peritonitis, treatment

Spontaneous bacterial peritonitis, treatment (off-label use):

Note: Some experts reserve for patients with existing kidney or severe hepatic impairment (eg, creatinine >1 mg/dL, BUN >30 mg/dL, or bilirubin >4 mg/dL) (Ref).

25% albumin: IV: Initial: 1.5 g/kg within 6 hours of diagnosis in combination with appropriate antimicrobial therapy, followed by 1 g/kg on day 3 (Ref); a possible alternative dose is 1 g/kg once daily for 2 days but it is not well studied (Ref). While the maximum albumin dose varies in clinical practice, some suggest not exceeding 100 g per dose (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: No dosage adjustment necessary for any degree of kidney impairment (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzed (large molecular weight of 66 kDa): No supplemental dose or dosage adjustment necessary (Ref).

Peritoneal dialysis: Unlikely to be dialyzed (large molecular weight): No dosage adjustment necessary (Ref).

CRRT: No dosage adjustment necessary (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Albumin solution: Pediatric drug information")

Dosage guidance:

Clinical considerations: Albumin 5% should be used in hypovolemic or intravascularly depleted patients; albumin 25% should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome). Dose depends on condition of patient.

Ascites with hypoalbuminemia

Ascites with hypoalbuminemia: Limited data available: Infants, Children, and Adolescents: 25% albumin: IV: 0.5 to 1 g/kg/dose over 2 to 3 hours; may repeat up to 3 times per day until albumin is >2.5 g/dL; maximum dose: 25 g/dose (Ref).

Hypovolemia, plasma volume expansion, including hypovolemic shock

Hypovolemia, plasma volume expansion, including hypovolemic shock: Infants, Children, and Adolescents: 5% albumin: IV: 0.5 to 1 g/kg/dose (10 to 20 mL/kg/dose) over 5 to 10 minutes (Ref). Note: Usual adult dose: 12.5 to 25 g/dose (250 to 500 mL/dose). May repeat after 15 to 30 minutes if response is not adequate.

Large volume paracentesis

Large volume paracentesis: Limited data available: Infants, Children, and Adolescents: 5% or 25% albumin: IV: 0.5 to 1 g/kg over 1 to 2 hours after paracentesis (Ref).

Nephrotic syndrome edema, refractory

Nephrotic syndrome edema, refractory: Infants, Children, and Adolescents: 25% albumin: IV: 0.5 to 1 g/kg/dose over 30 to 60 minutes followed by diuretic therapy (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosing adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Hepatic Impairment: Pediatric

There are no dosing adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Frequency not defined:

Cardiovascular: Flushing, heart failure, hypotension, tachycardia

Dermatologic: Pruritus, skin rash, urticaria

Gastrointestinal: Nausea, vomiting

Nervous system: Chills, rigors

Respiratory: Bronchospasm, dyspnea, pulmonary edema

Miscellaneous: Fever

Postmarketing:

Cardiovascular: Acute myocardial infarction, atrial fibrillation

Endocrine & metabolic: Hyperchloremic metabolic acidosis (Ritzenthaler 2016)

Gastrointestinal: Dysgeusia, sialorrhea

Hypersensitivity: Anaphylactic shock, anaphylaxis (Lozano 2019), hypersensitivity reaction (including severe hypersensitivity reaction), nonimmune anaphylaxis (Fujita 2007), type 1 hypersensitivity reaction (Wang 2019)

Nervous system: Headache

Miscellaneous: Febrile reaction

Contraindications

Hypersensitivity to albumin or any component of the formulation; severe anemia, heart failure; patients at risk of volume overload (eg, patients with kidney insufficiency, severe anemia, stabilized chronic anemia, or heart failure); dilution with sterile water for injection (may cause hemolysis or acute kidney failure).

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Severe allergic or anaphylactic reaction may occur. Discontinue immediately and manage appropriately if allergic or anaphylactic reactions are suspected.

• Coagulation abnormality: Large replacement volumes may result in coagulation abnormality. Monitor and replete with blood constituents if indicated.

• Electrolyte imbalance: Large replacement volumes may result in electrolyte imbalance. Monitor electrolytes and replace or maintain as indicated.

• Hemodynamic effects: Cardiac or respiratory failure, kidney failure, or increasing intracranial pressure can occur; closely monitor hemodynamic parameters in all patients.

• Hypervolemia/hemodilution: Use with caution in conditions where hypervolemia and its consequences or hemodilution may increase the risk of adverse effects (eg, heart failure, pulmonary edema, hypertension, hemorrhagic diathesis, cirrhosis, esophageal varices). Adjust rate of administration per hemodynamic status and solution concentration; monitor closely with rapid infusions. Avoid rapid infusions in patients with a history of cardiovascular disease (may cause volume overload and pulmonary edema). Discontinue at the first signs of cardiovascular overload (eg, headache, dyspnea, jugular venous distention, rales, abnormal elevations in systemic or central venous BP). All patients should be observed for signs of hypervolemia, such as pulmonary edema. Monitor BP.

Disease-related concerns:

• Critical illness: Avoid use for resuscitation in patients with traumatic brain injury due to increased mortality when used in this population (Myburgh 2007).

• Hepatic impairment: Use with caution in patients with hepatic impairment; protein load may exacerbate or precipitate encephalopathy.

• Kidney impairment: Use with caution in patients with kidney impairment; protein load may precipitate azotemia. Patients with chronic kidney insufficiency receiving albumin solution may be at risk for accumulation of aluminum and potential toxicities (eg, hypercalcemia, vitamin D refractory osteodystrophy, anemia, severe progressive encephalopathy).

Special populations:

• Sodium restricted patients: Use with caution in those patients for whom sodium restriction is necessary. Albumin 5% and 25% solutions contain 130 to 160 mEq/L sodium and are considered isotonic with plasma.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum (Kelly, 1989); toxic aluminum concentrations may be seen with high doses, prolonged use, or kidney dysfunction. Premature neonates are at higher risk due to immature kidney function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.

• Dilution: Do not dilute 5% albumin with sterile water for injection (may result in hemolysis and/or kidney failure).

• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.

• Latex: Packaging may contain natural latex rubber.

Warnings: Additional Pediatric Considerations

In neonates, use the 25% concentration with extreme caution due to risk of intraventricular hemorrhage (from rapid expansion of the intravascular volume); infuse slowly.

Due to the occasional shortage of 5% human albumin, 5% solutions may at times be prepared by diluting 25% human albumin with NS or with D5W (if sodium load is a concern); however, do not use sterile water to dilute albumin solutions, as this may result in hypotonic-associated hemolysis which can be fatal.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Intravenous:

Albumin-ZLB: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)

Generic: 25% (50 mL, 100 mL)

Solution, Intravenous [preservative free]:

Albuked 5: 5% (250 mL)

Albuked 25: 25% (50 mL, 100 mL)

Albuminex: 5% (250 mL, 500 mL); 25% (50 mL, 100 mL)

AlbuRx: 5% (250 mL, 500 mL)

Albutein: 5% (50 mL, 250 mL, 500 mL); 25% (20 mL, 50 mL, 100 mL)

Flexbumin: 5% (250 mL); 25% (50 mL, 100 mL)

Human Albumin Grifols: 25% (50 mL [DSC], 100 mL [DSC])

Kedbumin: 25% (50 mL, 100 mL)

Plasbumin-5: 5% (50 mL, 250 mL)

Plasbumin-25: 25% (20 mL, 50 mL, 100 mL)

Generic: 5% (100 mL, 250 mL, 500 mL); 25% (50 mL, 100 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Albuked 25 Intravenous)

25% (per mL): $1.15

Solution (Albuked 5 Intravenous)

5% (per mL): $0.23

Solution (Albumin Human Intravenous)

5% (per mL): $0.33

25% (per mL): $1.38 - $2.16

Solution (Albuminex Intravenous)

5% (per mL): $0.35

25% (per mL): $1.68

Solution (Albutein Intravenous)

5% (per mL): $0.22

25% (per mL): $1.12

Solution (Flexbumin Intravenous)

5% (per mL): $1.39

25% (per mL): $1.39

Solution (Human Albumin Grifols Intravenous)

25% (per mL): $2.16

Solution (Plasbumin-25 Intravenous)

25% (per mL): $1.18

Solution (Plasbumin-5 Intravenous)

5% (per mL): $0.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Alburex-5: 5% (100 mL, 250 mL, 500 mL)

Alburex-25: 25% (50 mL, 100 mL)

Plasbumin-5: 5% (50 mL, 250 mL, 500 mL)

Generic: 5% (50 mL, 100 mL, 250 mL, 500 mL); 25% (50 mL, 100 ea, 100 mL)

Administration: Adult

IV: For IV administration only. Note: Some products may require a filter; refer to product labeling. Rate of infusion is dependent upon use and clinical condition. See indication for specific rates in dosing or refer to institutional protocol. Too rapid infusion may result in volume overload. In emergencies, may administer as rapidly as necessary to improve clinical condition.

Manufacturer's recommended maximum administration rates:

5%, 25%: Typically, not recommended to exceed 1 to 2 mL/minute in patients without shock.

Albumin 25% may be given undiluted or diluted in normal saline. May give in combination or through the same administration set as saline or carbohydrates. Warm to room temperature before use if large volumes are administered. Use within 4 hours after entering package; discard unused portion. Do not use with ethanol or protein hydrolysates (precipitation may form).

Administration: Pediatric

Parenteral: IV: Note: Some products may require a filter; refer to product labeling. Rate of infusion is dependent upon use and clinical condition. See indication-specific rates in dosing or refer to institutional protocol. Too rapid infusion may result in vascular overload. In emergencies, may administer as rapidly as necessary to improve clinical condition.

Manufacturer recommended maximum administration rates:

5%: Do not exceed 1 mL/minute in patients with normal plasma volume (Ref).

25%: Do not exceed 1 to 2 mL/minute in patients without shock (Ref).

Use: Labeled Indications

Acute respiratory distress syndrome (25% solution only): To correct interstitial pulmonary edema (in combination with diuretics) and hypoproteinemia associated with acute respiratory distress syndrome.

Cirrhotic ascites, therapeutic large volume paracentesis (adjunctive agent): To maintain intravascular volume following removal of large-volume paracentesis in cirrhotic patients.

Hypovolemia: Plasma volume expansion and maintenance of intravascular volume in select patients for the treatment of hypovolemia (with or without shock). For replacement of volume deficit, 5% solution is generally preferred.

Neonatal hemolytic disease: Binds and detoxifies unconjugated bilirubin in severe hemolytic disease of the newborn during exchange transfusion.

Nephrosis (acute) (adjunctive agent): Treatment of edema in patients with acute nephrosis in combination with diuretics.

Ovarian hyperstimulation syndrome, treatment (25% solution only): As a plasma volume expander in fluid management for the treatment of severe ovarian hyperstimulation syndrome.

Plasma exchange, therapeutic: To avoid excessive hypoproteinemia, during certain types of exchange transfusion, or with the use of very large volumes or previously frozen or washed red cells.

Use: Off-Label: Adult

Hepatorenal syndrome type 1 or acute kidney injury in cirrhosis, treatment; Spontaneous bacterial peritonitis, treatment

Medication Safety Issues
Sound-alike/look-alike issues:

Albutein may be confused with albuterol.

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Reproductive Considerations

Albumin may be used for the treatment of severe ovarian hyperstimulation syndrome (OHSS) when hydration with NS is insufficient to achieve or maintain hemodynamic stability and urine output. Available data are insufficient to recommend use of albumin to reduce the risk OHSS in patients undergoing controlled ovarian stimulation (ASRM 2016; SOGC [Shmorgun 2017]).

Pregnancy Considerations

Albumin is an endogenous substance; products are prepared from pooled human plasma. Use in pregnant patients may be considered when contraindications to nonprotein colloids exist (Liumbruno 2009).

Breastfeeding Considerations

Endogenous albumin is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Dietary Considerations

Some products may contain potassium and/or sodium.

Monitoring Parameters

Monitor electrolytes, hemoglobin/hematocrit, and urine output regularly; monitor hemodynamic parameters, BP, heart rate, volume status, and signs and symptoms of pulmonary edema, central venous pressure, pulmonary artery occlusion pressure.

Mechanism of Action

Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space

Pharmacokinetics (Adult Data Unless Noted)

Half-life: 15 to 20 days

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Albiomin | Albuman | Human Albumin | Human albumin biotest;
  • (AR) Argentina: Albumina humana | Albumina serica humana unc | Albunorm | Alburex | Albutein | Buminate | Flexbumin | Uman albumin | Zenalb;
  • (AT) Austria: Albiomin | Albunorm | Alburex | Crealb | Flexbumin | Human Albumin | Humanalbumin | Humanalbumin haemo | Humanalbumin Kedrion;
  • (BE) Belgium: Albuman | Albumine human aventis behring | Albumine human aventis p.mer.msd | Albumine human croix rouge | Albumine human immuno | Albunorm | Alburex | Flexbumin | Hibumine | Octalbine;
  • (BG) Bulgaria: Albiomin | Albumin | Albumin Human Grifols | Albumin Human Immuno | Albumin Human Octapharma | Albunorm | Alburex | Human Albumin | Plasbumin | Uman albumin;
  • (BR) Brazil: Albiomin | Albumax | Albumina humana | Albumina humana grifols | Albumina serica humana normal | Albuminar | Alburex | Beribumin | Blaubimax | Octalbin | Plasbumin | Uman albumin | Vialebex;
  • (CH) Switzerland: Albuman | Albumin | Albumin csl | Flexbumin | Human albumin baxalta;
  • (CI) Côte d'Ivoire: Vialebex;
  • (CL) Chile: Albumina humana | Albutein;
  • (CN) China: Albumin prepared from human plasma | Albuminar | Alburaas | Ao da | Ao ke te fa ma | Bei lin | Human Albumin | Human albumin-Biotest | Plasbumin;
  • (CO) Colombia: Albuman berna | Albumina humana | Alburex | Albutein | Blaubimax | Buminate | Flexbumin | Human Albumin | Seralbumin | Uman albumin | Vialebex | Zenalb;
  • (CZ) Czech Republic: Albumin | Albumin lidsky | Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin baxter;
  • (DE) Germany: Albiomin | Albumine Lfb | Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin baxter | Human albumin immuno | Humanalbumin | Normal serum;
  • (DO) Dominican Republic: Albuman | Albumina humana | Albutein | Seralbumin;
  • (EC) Ecuador: Albuman | Albumina humana | Albunorm | Alburx;
  • (EE) Estonia: Albumin | Albunorm | Flexbumin | Human Albumin;
  • (EG) Egypt: Albapure | Albumin-GCPD | Albuminar | Albuminativ | Albunorm | Alburaas | Albutein | Buminate | Cealb | Human Albumin | Human albumin octapharma | Plasbumin | Vialebex | Zenalb;
  • (ES) Spain: Albiomin | Albumina humana | Albumina Humana Behring | Albumina humana grifols | Albumina humana kedrion | Albunorm | Albuplan | Alburex | Flexbumin | Octalbin | Plasbumin;
  • (ET) Ethiopia: Albunorm;
  • (FI) Finland: Albumin | Albumin baxter | Albuminativ | Albunorm | Alburex | Albutein | Flexbumin | Octalbin;
  • (FR) France: Albumine baxter | Albumine Humaine | Albumine humaine baxter | Albunorm | Alburex | Flexbumin | Octalbine | Vialebex | Ydralbum;
  • (GB) United Kingdom: Albunorm | Alburex | Albutein | Flexbumin | Human Albumin | Human albumin grifols | Octalbin | Zenalb | Zenbumin;
  • (GR) Greece: Albiomin | Albuman | Albuminativ | Albumine Lfb | Alburex | Flexbumin | Human Albumin | Human albumin kedrion | Human albumin zlb | Human albumin/baxalta | Human albumin/grifols | Plasbumin | Zenalb;
  • (HK) Hong Kong: Albumex | Albutein | Buminate | Gaipharm albumin | Human Albumin | Human albumin biotest | Kamapharm albumin human | Normal serum album | Plasbumin | Uman albumin | Vialebex;
  • (HR) Croatia: Albumin (ljudski) 20% | Albumin ljudski 50 g/l | Human Albumin 5% Octapharma;
  • (HU) Hungary: Albunorm | Alburex | Human Albumin | Human albumin kedrion | Human albumin octa | Plazmaprotein;
  • (ID) Indonesia: Albapure | Albuminar | Albunorm | Alburaas | Albutein | Cealb | Farmin | Human albumin 20% behring | Human albumin grifols | Octalbin | Plasbumin | Robumin | Zenalb;
  • (IE) Ireland: Albuminativ | Albunorm | Flexbumin | Human albumin baxalta;
  • (IL) Israel: Human Albumin | Kamapharm albumin human;
  • (IN) India: Alba | Albudac | Albukind | Albull | Albumed | Albumin | Albupan | Albuprime | Alburel | Alburel t | Albuspey | Albutein | Albuzest | Buminate | Flexbumin | Human Albumin | Human albumin grifols | Plasvex | Verbumin | Volumin;
  • (IT) Italy: Albiomin | Albital | Albuman berna | Albumeon | Albumina grifols | Albumina lfb | Albumina Uman Kabi | Albumina umana | Albumina Umana Con | Albumina umana mf | Albunorm | Alburex | Albutein | Flexbumin | Haimalbumin | Octalbin | Uman albumin;
  • (JO) Jordan: Albuman;
  • (JP) Japan: Albumin baxter | Albumin Behring | Albumin benesis | Albumin cutter | Albumin kaketsuken | Albumin Mitsubishi | Albuminar | Buminate | Human serum albumin | Kenketu albumin | Medway | Sekijuji albumin;
  • (KE) Kenya: Albumin gcc | Alburel;
  • (KR) Korea, Republic of: Albumin | Gcc albumin | Sk albumin;
  • (KW) Kuwait: Albuman | Alburex | Human Albumin | Human albumin csl behring | Plasbumin | Uman albumin;
  • (LB) Lebanon: Albuman | Albutein | Human Albumin | Vialebex | Ydralbum;
  • (LT) Lithuania: Albumin | Albumin baxter | Albumin lidsky | Albumin Placentary | Albunorm | Cilveka albumina | Flexbumin | Human Albumin | Human albumin biotest | Human albumin csl behring | Spr | Zmogaus albuminas NKC;
  • (LV) Latvia: Albumin | Albumin lidsky | Albumin Placentary | Albunorm | Cilveka albumina | Human Albumin | Human albumin csl behring | Spr;
  • (MA) Morocco: Albumine Humaine | Albumine Human | Albunorm | Vialebex;
  • (MX) Mexico: Albumar | Albumina | Albumina humana | Albumina Humana Behring | Albumina humana grifols | Albuminar | Albunate | Albutein | Flexbumin | Hi bumin | Kedrialb | Octalbin | Probialbumin | Seralbumin | Seroalbumina | Seroalbumina gi ce | Seroalbumina Humana | Seroalbumina Loeffler | Vanderbumin | Zenalb;
  • (MY) Malaysia: Albapure | Albuman berna | Albumin-kgcc | Albunorm | Alburx | Albutein | Buminate | Human Albumin | Human albumin behring | Plasbumin | Zenalb;
  • (NL) Netherlands: Albuman | Albunorm | Alburex | Cealb | Flexbumin;
  • (NO) Norway: Albumin baxter | Albumin Octapharma | Albunorm | Alburex | Flexbumin | Human albumin biotest;
  • (PE) Peru: Acebumin | Albuman | Albumina humana | Albumina humana Octapharma | Alburex 20 | Seralbumin-25;
  • (PH) Philippines: Albuman | Albumax | Albumeon | Albunorm | Alburel | Alburx | Albutein | Buminate | Flexbumin | Human albumin behring | Plasbumin | Plasbutein | Rescuerel | Zenalb;
  • (PK) Pakistan: Albuman | Albumeon | Albumin | Human Albumin | Plasbumin;
  • (PL) Poland: Albumin human salzarm | Albumin ludzka | Albumina ludzka | Albunorm | Alburex | Flexbumin | Fortalbia | Human Albumin | Uman albumin;
  • (PR) Puerto Rico: Albuked | Albumin-zlb | Albuminar | Albutein | Buminate | Flexbumin | Plasbumin | Plasbumin-5 Low Albumin;
  • (PT) Portugal: Albumina humana baxter | Albumina Humana Behring | Albumina humana grifols | Albumina humana kedrion | Albumina humana Octapharma | Albunorm | Alburex;
  • (PY) Paraguay: Albiomin | Albumin gcc | Albumina humana | Albumina humana blausiegel | Albumina humana duncan | Albumina humana eron | Albumina humana grifols | Albumina humana nortelab | Albumina humana quimfa | Albumina humana rhedquin | Albunorm | Alburel | Alburx | Kedrion Uman Albumin | Totalbumina;
  • (QA) Qatar: Human Albumin Behring | Human Albumin Biotest;
  • (RO) Romania: Albiomin | Albumeon | Albumina umana baxter | Albumina umana grifols | Albumina umana kedrion | Albunorm | Alburex | Human Albumin | Vialebex;
  • (RU) Russian Federation: Albiomin | Albumen | Albumin | Albumin Donor | Albumin Human Biotest | Albumin human dess | Albumin Placentary | Alburex | Human Albumin | Human albumin biotest | Plasbumin | Uman albumin | Zenalb;
  • (SA) Saudi Arabia: Alburex | Albutein | Flexbumin | Human Albumin | Human albumin grifols | Plasbumin | Zenalb;
  • (SE) Sweden: Albumer | Albumin | Albumin baxter | Albumin Behring | Albumin Hemasure | Albumin Immuno | Albumin Octapharma | Albuminar | Albuminativ | Albunorm | Alburex | Albutein | Flexbumin;
  • (SG) Singapore: Albutein | Buminate | Human Albumin | Zenalb Human Albumin;
  • (SI) Slovenia: Albumin Humani | Flexbumin | Humani albumin csl behring;
  • (SK) Slovakia: Albumin | Albumin Human Lidsky | Albumin lidsky | Albunorm | Alburex | Flexbumin | Human albumin csl behring;
  • (TH) Thailand: Albuman berna | Albumin 20 trcs | Albumin Octapharma | Albumin-kgcc | Albuminar | Alburaas | Albutein | Buminate | Flexbumin | Human Albumin | Human albumin 20% behring | Human albumin grifols | Human serum albumin | Kamapharm albumin (human) | Zenalb;
  • (TN) Tunisia: Albiomin | Albumin | Albumine | Albumine Humaine | Albunorm | Vialebex;
  • (TR) Turkey: Alba | Albiomin | Albuman | Albumin | Albumin Hemasure | Albuminar | Buminate | Cealb | Flexbumin | Human Albumin | Plasbumin | Vialebex | Zenalb;
  • (TW) Taiwan: Albapure | Albuman berna | Albuminar | Albunorm | Albutein | Buminate albumin | Flexbumin | Human Albumin | Plasbumin;
  • (UA) Ukraine: Albumin | Albumin Donor | Albumin Placentary | Albuminum human | Albunorm | Albuven | Flexbumin | Human Albumin;
  • (UG) Uganda: Albunorm;
  • (UY) Uruguay: Albuman | Albumina gcc | Albumina humana | Albunorm | Blaubimax | Seralbumin;
  • (VE) Venezuela, Bolivarian Republic of: Albumina humana;
  • (ZA) South Africa: Albusol;
  • (ZW) Zimbabwe: Alburel
  1. Abd Elaal MM, Zaghloul SG, Bakr HG, et al. Evaluation of different therapeutic approaches for spontaneous bacterial peritonitis. Arab J Gastroenterol. 2012;13(2):65-70. doi:10.1016/j.ajg.2012.06.003 [PubMed 22980594]
  2. Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9-29. doi:10.1136/gutjnl-2020-321790 [PubMed 33067334]
  3. Albuked 5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
  4. Albuked 20 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
  5. Albuked 25 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
  6. Albuminex 25% (albumin [human]) [prescribing information]. Durham, NC: Bio Products Laboratory; received February 2019.
  7. Albuminex 5% (albumin [human]) [prescribing information]. Durham, NC: Bio Products Laboratory; August 2018.
  8. AlbuRx 5 (albumin [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; July 2020.
  9. Albutein (albumin) [prescribing information]. Los Angeles, CA: Grifols Biologicals Inc; July 2021.
  10. Albutein 5 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.
  11. Albutein 20 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.
  12. Albutein 25 (albumin [human]) [prescribing information]. Clayton, NC: Grifols Therapeutics Inc; August 2015.
  13. Albutein 25 (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; June 2018.
  14. Albutein FlexBag 25% (albumin [human]) [prescribing information]. Los Angeles, CA: Grifols Biologicals LLC; August 2021.
  15. Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
  16. American Thoracic Society (ATS). Evidence-Based Colloid Use in the Critically Ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med. 2004;170(11):1247-1259. [PubMed 15563641]
  17. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690-1697. doi:10.1002/hep.510290629 [PubMed 10347109]
  18. Based on expert opinion.
  19. Belver J, Muñoz EA, Ballesteros A, et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod. 2003;18(11):2283-2288. [PubMed 14585874]
  20. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181. [PubMed 22095893]
  21. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PubMed 33942342]
  22. Boyer TD, Sanyal AJ, Wong F, et al; REVERSE Study Investigators. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579-1589.e2. doi:10.1053/j.gastro.2016.02.026 [PubMed 26896734]
  23. Brierley J, Carcillo JA, Choong K, et al. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine. Crit Care Med. 2009;37(2):666-688. [PubMed 19325359]
  24. Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med. 2005;33(10)(suppl):S301-S306. [PubMed 16215351]
  25. Caraceni P, Angeli P, Prati D, et al; Italian Association for the Study of the Liver (AISF); Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus. 2016;14(1):8-22. [PubMed 26820615]
  26. Cavallin M, Kamath PS, Merli M, et al; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62(2):567-574. doi:10.1002/hep.27709 [PubMed 25644760]
  27. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology. 2016;63(3):983-992. [PubMed 26659927]
  28. Centers for Disease Control and Prevention. Hemolysis Associated With 25% Human Albumin Diluted With Sterile Water - United States, 1994-1998. MMWR. 1999;48(8):157-159. http://www.cdc.gov/mmwr/preview/mmwrhtml/00056596.htm [PubMed 10079061]
  29. China L, Freemantle N, Forrest E, et al; ATTIRE Trial Investigators. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808-817. doi:10.1056/NEJMoa2022166 [PubMed 33657293]
  30. Cloherty JP, Eichenwald EC, Stark AR, eds. Manual of Neonatal Care. 7th ed. Lippincott Williams & Wilkins; 2012.
  31. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. [PubMed 23353941]
  32. Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Lippincott Williams & Wilkins; 2017.
  33. El-Desoki Mahmoud EI, Abdelaziz DH, Abd-Elsalam S, Mansour NO. Norepinephrine is more effective than midodrine/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol. 2021;12:675948. doi:10.3389/fphar.2021.675948 [PubMed 34276366]
  34. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024 [PubMed 29653741]
  35. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337 [PubMed 34605781]
  36. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  37. Finfer S, Bellomo R, Boyce N, et al. A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. SAFE Study Investigators. N Engl J Med. 2004;350(22):2247-2256. [PubMed 15163774]
  38. Flexbumin 5% (albumin human) [prescribing information]. Lexington, MA: Baxalta US Inc; November 2021.
  39. Flexbumin 25% (albumin human, USP) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.
  40. Fortin PM, Bassett K, Musini VM. Human albumin for intradialytic hypotension in haemodialysis patients. Cochrane Database Syst Rev. 2010;(11):CD006758. [PubMed 21069691]
  41. Fujita A, Kitayama M, Hirota K. Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting. J Anesth. 2007;21(3):396-398. doi:10.1007/s00540-007-0512-3 [PubMed 17680193]
  42. Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenterol Nutr. 2011;52(5):503-513. [PubMed 21464748]
  43. Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747-757. [PubMed 19651590]
  44. Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420. doi:10.1136/bmjresp-2019-000420 [PubMed 31258917]
  45. Human albumin 25% [prescribing information]. Research Triangle Park, NC: Grifols USA; April 2012.
  46. Jee BC, Suh CS, Kim YB, et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest. 2010;70(1):47-54. [PubMed 20173327]
  47. Kattwinkel J, Perlman JM, Aziz K, et al. Part 15: neonatal resuscitation: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18)(suppl 3):S909-S919. [PubMed 20956231]
  48. Kedbumin (albumin human) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma Inc; May 2016.
  49. Kedbumin (albumin) [prescribing information]. Fort Lee, NJ: Kedrion Biopharma Inc; June 2011.
  50. Kelly AT, Short BL, Ranis TC, May JC, Progar JJ. Aluminum toxicity and albumin. ASAIO Trans. 1989;35(3):674-676. [PubMed 2597561]
  51. Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18)(suppl 3):S876-S908. [PubMed 20956230]
  52. Kliegman RM, St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Saunders Elsevier; 2020.
  53. Knoll GA, Grabowski JA, Dervin GF, et al. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. J Am Soc Nephrol. 2004;15(2):487-492. [PubMed 14747397]
  54. Kramer RE, Sokol RJ, Yerushalmi B, et al. Large-volume paracentesis in the management of ascites in children. J Pediatr Gastroenterol Nutr. 2001;33(3):245-249. [PubMed 11593116]
  55. Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and effectiveness of norepinephrine outside the intensive care setting for treatment of hepatorenal syndrome. Liver Transpl. 2021;27(8):1095-1105. doi:10.1002/lt.26065 [PubMed 33837624]
  56. Lane ER, Hsu EK, Murray KF. Management of ascites in children. Expert Rev Gastroenterol Hepatol. 2015;9(10):1281-1292. [PubMed 26325252]
  57. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossettias G; Italian Society of Transfusion Medicine and Immunohaematology (SIMTI). Recommendations for the use of albumin and immunoglobulins. Blood Transfus. 2009;7(3):216-34. doi:10.2450/2009.0094-09 [PubMed 19657486]
  58. Lynch SK, Mullett MD, Graeber JE, et al. A Comparison of Albumin-Bolus Therapy Versus Normal Saline-Bolus Therapy for Hypotension in Neonates. J Perinatol. 2008;28(1):29-33. [PubMed 17989698]
  59. Maitland K, Kiguli S, Opoka RO, et al. Mortality After Fluid Bolus in African Children With Severe Infection. N Engl J Med. 2011;364(26):2483-2495. [PubMed 21615299]
  60. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;30(10):2175-2182. doi:10.1097/00003246-200210000-00001 [PubMed 12394941]
  61. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33(8):1681-1687. doi:10.1097/01.ccm.0000171539.47006.02 [PubMed 16096441]
  62. Martín-Llahí M, Pépin MN, Guevara M, et al; TAHRS Investigators. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134(5):1352-1359. [PubMed 18471512]
  63. Moreno Lozano L, Galindo Bonilla P, Borja Segade J, Extremera Ortega A, Gómez Torrijos E, García Rodríguez R. Human serum albumin induced anaphylaxis in a patient with good tolerance to human plasma. J Investig Allergol Clin Immunol. 2019;29(1):51-53. doi:10.18176/jiaci.0325 [PubMed 30785101]
  64. Myburgh J, Cooper DJ, Finfer S, et al; SAFE Study Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group; Australian Red Cross Blood Service; George Institute for International Health. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357(9):874-884. doi:10.1056/NEJMoa067514 [PubMed 17761591]
  65. Oca MJ, Nelson M, Donn SM. Randomized trial of normal saline versus 5% albumin for the treatment of neonatal hypotension. J Perinatol. 2003;23(6):473-476. [PubMed 13679934]
  66. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36(4, pt 1):941-948. [PubMed 12297842]
  67. Plasbumin (albumin) [prescribing information]. Research Triangle Park, NC: Talecris Biotherapeutics Inc; April 2010.
  68. Plasbumin-5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2020.
  69. Plasbumin-5 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; September 2017.
  70. Plasbumin-20 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
  71. Plasbumin-25 (albumin [human]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; August 2020.
  72. Practice Committee of the American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril. 2016;106(7):1634-1647. doi:10.1016/j.fertnstert.2016.08.048 [PubMed 27678032]
  73. Refer to manufacturer's labeling,
  74. Ritzenthaler T, Grousson S, Dailler F. Hyperchloremic metabolic acidosis following plasma exchange during myasthenia gravis crisis. J Clin Apher. 2016;31(5):479-480. doi:10.1002/jca.21432 [PubMed 26390995]
  75. Roberts JS and Bratton SL, Colloid volume expanders. Problems, pitfalls, and possibilities. Drugs. 1998;55(5):621-630. [PubMed 9585860]
  76. Robinson RF, Nahata MC, Mahan JD, Batisky DL. Management of nephrotic syndrome in children. Pharmacotherapy. 2003;23(8):1021-1036. [PubMed 12921248]
  77. Romanelli RG1, La Villa G, Barletta G. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12(9):1403-1407. [PubMed 16552809]
  78. Runyon BA. Hepatorenal syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 4, 2021a.
  79. Runyon BA. Spontaneous bacterial peritonitis in adults: treatment and prophylaxis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 20, 2022b.
  80. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi:10.1002/hep.26359 [PubMed 23463403]
  81. Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites. Curr Gastroenterol Rep. 2003;5(3):240-246. [PubMed 12734047]
  82. Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol. 2013;11(2):123-130. doi:10.1016/j.cgh.2012.11.007 [PubMed 23178229]
  83. Shmorgun D, Claman P. No-268-the diagnosis and management of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can. 2017;39(11):e479-e486. doi:10.1016/j.jogc.2017.09.003 [PubMed 29080733]
  84. Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut. 2007;56(4):597-599. doi:10.1136/gut.2006.113050 [PubMed 17369392]
  85. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603 [PubMed 10432325]
  86. UHC Clinical Practice Advancement Center. Technology assessment: albumin, nonprotein colloid, and crystalloid solutions. Oak Brook, IL: University Health System Consortium; May 2000.
  87. Uhlig C, Silva PL, Deckert S, Schmitt J, de Abreu MG. Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18(1):R10. doi:10.1186/cc13187 [PubMed 24405693]
  88. Vermeulen LC Jr, Ratko TA, Erstad BL, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995;155(4):373-379. [PubMed 7848020]
  89. Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(1):188-196. [PubMed 20579987]
  90. Wang KY, Friedman DF, DaVeiga SP. Immediate hypersensitivity reaction to human serum albumin in a child undergoing plasmapheresis. Transfusion. 2019;59(6):1921-1923. doi:10.1111/trf.15194 [PubMed 30758852]
  91. Wong F, Pappas SC, Curry MP, et al; CONFIRM Study Investigators. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828. doi:10.1056/NEJMoa2008290 [PubMed 33657294]
  92. Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18)(suppl 2):S543-S560. [PubMed 26473001]
Topic 9376 Version 320.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟